Pharmaceutical

Rhythm expands obesity portfolio with Phase II weight loss drug for $100m

Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB54640 for $100m in cash and equity.

Jan 5, 2024 - 18:00
Rhythm expands obesity portfolio with Phase II weight loss drug for $100m
Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB54640 for $100m in cash and equity.
Read the original article

Tags:

Previous Article

Pharmaceutical Technology Excellence Awards 2023: KAI Conversations

Next Article

Boehringer and 3T Biosciences partner to develop cancer immunotherapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Nearly 1 in 10 teens globally have used ‘budget Ozempic’ laxatives and other risky weight loss products, per study

Nearly 1 in 10 teens globally have used ‘budget Ozempic...

Jan 10, 2024

STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies

STAT+: Pharma loses a key battle over a state law conce...

Mar 13, 2024

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Glenmark Pharma to divest 75% stake in life sciences un...

Sep 23, 2023